Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuma Sugimoto

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
BMC Urology|November 10, 2022
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinomaKazuma Sugimoto, Satoru Taguchi, Kenjiro Kishitani, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 9, 2024
Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomyYuji Hakozaki, Yuta Yamada, Tetsuya Fujimura, et al.
Scientific Reports|March 31, 2024
Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomyYuta Yamada, Yoichi Fujii, Shigenori Kakutani, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 23, 2022
Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020)Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
BMC Urology|November 10, 2022
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinomaKazuma Sugimoto, Satoru Taguchi, Kenjiro Kishitani, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 9, 2024
Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomyYuji Hakozaki, Yuta Yamada, Tetsuya Fujimura, et al.
Scientific Reports|March 31, 2024
Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomyYuta Yamada, Yoichi Fujii, Shigenori Kakutani, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 23, 2022
Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020)Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 2